胱抑素C联合血小板体积对非ST段抬高急性冠状动脉综合征危险分层的预测价值
摘要
非ST段抬高急性冠状动脉综合征（NSTE-ACS）患者临床表现轻重不一，预后差异很大，对其进行早期危险分层，制定相应的治疗策略，能最大限度地改善预后。目前，已有多种心血管疾病危险评估系统，如全球急性冠脉事件注册（global registry of acute coronary events，GRACE）危险评分、TIMI评分、PURSUIT评分等，其中GRACE评分被认为是最有效的预测NSTE-ACS死亡风险的工具之一。然而由于其评估系统较为复杂，使临床应用受到限制，故积极找寻简单、快速及准确的评估系统仍为现阶段研究的热点。近年来的研究发现胱抑素C（Cys-C）参与心血管疾病诸多的病理生理过程，而血小板作为NSTE-ACS发病过程中的一个必备条件，与其发生密切相关。为此，本研究观察NSTE-ACS患者入院时Cys-C、血小板体积（MPV）水平变化，并追踪随访6个月内发生主要不良心脏事件（MACE）的情况，旨在探讨其在NSTE-ACS危险分层中的应用价值。
出处
《中国药物与临床》
CAS
2015年第6期827-830,共4页
Chinese Remedies & Clinics
基金
山西省科技厅攻关项目(20140313015-11)
参考文献8
-
1Isilak Z,Kardesoglu E,Aparci M,et al.Comparison of clinicalrisk assessment systems in predicting three-vessel coronary arterydisease and angiographic culprit lesion in patients with non-STsegment elevated myocardial infarction/unstable angina pectoris[J].Kardiol Pol,2012,70(3):242-50.
-
2Aragam KG,Tamhane UU,Kline-Rogers E,et al.Does simplicitycompromise accuracy in ACS risk prediction?A retrospectiveanalysis of the TIMI and GRACE risk scores[J].PLo S One,2009,4(11):e7947.
-
3Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction-executive summary[J].JAm coll Cardiol,2007,50(7):652-726.
-
4Tomas J,Bertil L,Stefan J,et al.Cystatin C:a novel predictor ofoutcome in suspected or confirmed non-st-elevation acute coro-nary syndrome[J].Circulation,2004,110(16):2342-2348.
-
5Kilic T,Oner G,Ural E,et al.Comparison of the long-term prognostic value of cystatin C to other indicators of renal function,markers of inflammation and systolic dysfunction among patientswith acute coronary syndrome[J].Atheroslcerosis,2009,207(2):552-558.
-
6Smith NM,Pathansali R,Bath PM,Platelets and stroke[J].VascMed,1999,4(3):165-172.
-
7Yilmaz MB,Cihan G,Guray Y,et al.Role of mean platelet volume in triaging acute coronary syndromes[J].J Thromb Thrombolysis,2008,26(1):49-54.
-
8莫文宏,杨帆,王红,谭保平,何柳平,吴昊.冠心病患者血小板CD41^+CD62^+与胱抑素C的相关性研究[J].实用医学杂志,2012,28(20):3369-3371. 被引量：3
二级参考文献12
-
1Okura T, Jotoku M, Irita J, et al.Association between cystatin C and inflammation in patients with essential hypertension [J]. Clin Exp Nephrol, 2010,14(6) :584-588.
-
2Luc G, Bard J M, Lesueur C, et al. Plasma cystatin-C and development of coronary heart disease:The PRIME Study [J]. Atherosclerosis, 2006,185 (2) : 375-380.
-
3Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods [J]. Clin Chem, 2005,51 ( 8 ) : 957-965.
-
4Angiolillo D J, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [ J ]. Diabetes, 2005,54 (8) : 2430-2435.
-
5Bonfanti R, Furie B C, Furie B, et al. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells [J]. Blood, 1989,73(5) : 1109-1112.
-
6Yashiro M, Kamata T, Segawa H, et al. Comparisons of cystatin C with creatinine for evaluation of renal unction in chronic kidney disease [J]. Clin Exp Nephrol, 2009,13(6): 598-604.
-
7Willems D, Wolff F, Mekhali F, et al. Cystatin C for early detection of renal impairment in diabetes [J]. Clin Biochem, 2009,42(1-2) : 108-110.
-
8El-Shafey E M, El-Nagar G F, Selim M F, et al. Is serum cystatin C an accurate endogenous marker of glomerular filtration rate for detection of early renal impairment in patients with type 2 diabetes mellitus [J]? Ren Fail, 2009,31(5):355-359.
-
9Gao C, Zhong L, Gao Y, et al. Cystatin C levels are associated with the prognosis of systolic heart failure patients [J]. Arch Cardiovasc Dis, 2011,104( 11 ) :565-571.
-
10Lee M, Saver J L, Huang W H, et al. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis [J]. Circ Cardiovasc Qual Outcomes, 2010,3 (6) : 675-683.
-
1马春平,张晓梅.MPV、PDW二项指标与肿瘤的关系(摘要)[J].江西医学检验,1996,14(1):18-19.
-
2汪亮,陈维永,何莉,赵承鹏.脂肪肝患者平均血小板体积与颈动脉粥样硬化的相关性探讨[J].浙江临床医学,2015,17(1):68-69. 被引量：2
-
3丁丽,强蕴蕴,郭清芳,宋秋兰.乙型肝炎患者血小板计数及平均血小板体积检测[J].西安医科大学学报,1995,16(4):431-431. 被引量：27
-
4李世雪,张学勇,何东华.血栓性疾病276例血小板体积临床分析[J].中国实用内科杂志,2002,22(11):686-686. 被引量：9
-
5江美芝,邹小青.老年女性高血脂症血浆中血小板与血脂变化的相关性分析[J].黑龙江医学,2005,29(7):491-492.
-
6欧阳敏.血小板分布宽度在血栓前状态中的临床意义[J].江西医药,2007,42(5):424-425. 被引量：10
-
7简春宣,舒慧.英夫利昔单抗联合不同免疫抑制剂治疗溃疡性结肠炎的疗效比较[J].结直肠肛门外科,2016,22(5):506-509. 被引量：6
-
8褚新建,孟慧琴.血小板活化在肺血栓栓塞症中的临床意义探讨[J].中国中医药咨讯,2010(35):64-64.
-
9赵雪梅,冯玉兰.奥扎格雷治疗对糖尿病患者血小板参数的影响[J].安徽医学,2011,32(12):1996-1997.
-
10邹刚.重型肝炎患者小板数量及体积的变化[J].实用肝脏病杂志,2003,6(1).
